Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) - USD ($)						3 Months Ended		9 Months Ended
	May 20, 2024	May 13, 2024	Jun. 16, 2021	Mar. 26, 2021	Jul. 18, 2016	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Apr. 25, 2024	Dec. 31, 2023	Aug. 24, 2022
Loss Contingencies [Line Items]
Common stock, shares issued						2,234,328		2,234,328				1,380,633
Accounts payable, current						$ 2,612,000		$ 2,612,000				$ 4,328,000
Stock issued during period, value, issued for services							$ 115,000	1,300,000	$ 430,000
Research and development expense						1,307,000	$ 1,364,000	3,868,000	5,109,000
2021 Scientific Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense			$ 2,100,000
Research and development expense								0	192,000
Unbilled and unaccrued amounts						0		0
2023 Sponsored Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense	$ 1,700,000
Research and development expense								863,000	0
Unbilled and unaccrued amounts						$ 862,000		862,000
2016 Patent Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense								145,000	0
Proceeds from upfront amount		$ 145,000			$ 200,000
Maintenance fee		100,000			$ 100,000
Royalty fee percentage					4.00%
Performance milestone payments		3,100,000			$ 3,100,000
Sales milestone payments		1,000,000			1,000,000
Gross sales		250,000,000			250,000,000
Sales revenue		5,000,000			5,000,000
Cumulative gross sales		500,000,000			$ 500,000,000
Royalty expense		250,000
Royalty expense		2,000,000
Royalty expense		$ 5,000,000
2016 Patent Exclusive License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage		5.00%			6.00%
2016 Patent Exclusive License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage		1.00%
2016 Patent Exclusive License Agreement [Member] \| 2017 through 2020 [Member]
Loss Contingencies [Line Items]
Maintenance fee					$ 200,000
2016 Patent Exclusive License Agreement [Member] \| 2022 [Member]
Loss Contingencies [Line Items]
Annual royalty payments					250,000
2016 Patent Exclusive License Agreement [Member] \| 2025 [Member]
Loss Contingencies [Line Items]
Maintenance fee		$ 50,000
Annual royalty payments					2,000,000
2016 Patent Exclusive License Agreement [Member] \| 2027 [Member]
Loss Contingencies [Line Items]
Annual royalty payments					$ 5,000,000
2021 Patent License Agreement [Member]
Loss Contingencies [Line Items]
Maintenance fee				$ 2,000,000
Annual royalty payments				250,000
Performance milestone payments				3,100,000
Sales milestone payments				1,000,000
Gross sales				250,000,000
Sales revenue				5,000,000
Cumulative gross sales				500,000,000
Upfront license fee				20,000
License maintenance fee, receivable				$ 5,000
2021 Patent License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage				5.00%
2021 Patent License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage				2.50%
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Research and development expenses								1,365,000	3,691,000
Cash payments								$ 3,432,000	$ 1,710,000
Common stock, shares issued						127,597	57,437	127,597	57,437
Accounts payable, current						$ 810,000	$ 1,120,000	$ 810,000	$ 1,120,000
Cytovance Biologics Inc [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
Research and development expenses								$ 1,365,000	$ 3,691,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage										5.00%	9.90%		4.90%